Research programme: orexin 1 inhibitors - Evotec

Drug Profile

Research programme: orexin 1 inhibitors - Evotec

Alternative Names: C4X 3256; Orexin 1 antagonist - Evotec

Latest Information Update: 04 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Evotec AG
  • Developer C4X Discovery; Evotec AG
  • Class Drug withdrawal therapies
  • Mechanism of Action Orexin receptor type 1 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Drug abuse

Highest Development Phases

  • Preclinical Drug abuse

Most Recent Events

  • 29 Mar 2018 C4X Discovery and Indivior enter into a licensing agreement for the development of C4X 3256 for Drug-abuse
  • 12 Jul 2016 C4X Discovery Holdings acquires drug discovery technologies from from MolPlex Ltd
  • 05 Apr 2016 C4X Discovery plans a phase I trial for Drug abuse
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top